National Cancer Institute, Acquisition Management Branch, TBS, 6120 Executive Blvd, EPS/Rm 603 Bethesda, MD 20892-7220

B -- EARLY DETECTION OF ESOPHAGEAL CANCER SOL N02-SC-91019-30 POC Elsa B. Carlton, Contract Specialist, (301)435-3811 The National Cancer Institute (NCI) intends to negotiate with the Cancer Institute, Chinese Academy of Medical Sciences, Beijing, People's Republic of China, for the evaluation of techniques for the early detection and treatment of squamous esophageal cancer. Over 1200 patients with squamous dysplasia or early invasive cancer of the esophagus will be required for this project. This study will be conducted over a 5-year period. The government intends to award a fixed-price contract. Most patients with these lesions are asymptomatic, so the subjects needed for this study will have to be identified from an asymptomatic high-risk population. For this reason, the project will be carried out in the Linxian region of China, a geographic area with the highest rates of esophageal cancer in the world. The combination of an asymptomatic high-risk population and an experienced research team with proven successful activities similar to those needed in the current project makes the Cancer Institute, Chinese Academy of Medical Sciences uniquely qualified to evaluate the early detection and treatment methods that will be evaluated. No such study population exists in the United States, making competition infeasible. RFP No. N02-SC-91019-30 will be issued 45 days from the date of this synopsis. Authority: 41 U.S.C. 253(c)(1), as set forth in FAR 6.302-1. See numbered Note 22. No collect calls will be accepted. Posted 02/09/99 (W-SN296371). (0040)

Loren Data Corp. http://www.ld.com (SYN# 0012 19990211\B-0001.SOL)